Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3879835 | 0.85 | MRGPRX4 (0.44) | L3MBTL1TDP1NPC1ACHERAB9A | |
| SCHEMBL9929012 | 0.83 | ACHE (0.54) | TDP1ACHEALDH1A1MAPTPOLB | |
| SCHEMBL3833650 | 0.82 | L3MBTL1 (0.53) | L3MBTL1TDP1NPC1ACHERAB9A | |
| SCHEMBL4805336 | 0.82 | CES2 (0.43) | NPC1RAB9AMAPTHTTSMN1; SMN2 | |
| SCHEMBL31126239 | 0.82 | CES2 (0.43) | NPC1RAB9AMAPTHTTSMN1; SMN2 | |
| SCHEMBL28621964 | 0.81 | KMT2A (0.52) | HTR2ASLC6A4KCNH2L3MBTL1TDP1 | |
| SCHEMBL17355743 | 0.80 | RAB9A (0.42) | HTR2ASLC6A4KCNH2TDP1NPC1 | |
| SCHEMBL17355718 | 0.79 | ELANE (0.38) | HTR2ASLC6A4KCNH2L3MBTL1TDP1 | |
| SCHEMBL17355713 | 0.79 | ELANE (0.51) | HTR2ASLC6A4KCNH2L3MBTL1TDP1 | |
| SCHEMBL17355711 | 0.79 | ACHE (0.58) | L3MBTL1TDP1NPC1ACHERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009534-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| US-20080009534-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| US-20080009534-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| WO-2008006044-A2 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008006044-A2 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009534-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | GPR119, LIPC, CEL | HTR2A 3025/4885SLC6A4 1901/4885KCNH2 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.